Diabetes Mellitus, Type 2
Conditions
Interventions
investigational material(s)
Generic name etc : Ticagrelor 60 mg
INN of investigational material : ticagrelor
Therapeutic category code : 339 Other agents relating to blood and body fluides
Dosage and
Sponsors
AstraZeneca KK
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Men or women 50 years of age or more with type 2 diabetes mellitus on treatment with a glucose lowering medication since at least 6 months, and either documented coronary artery occlusive disease or previous revascularization of a coronary artery.
Exclusion criteria
Exclusion criteria: - History of myocardial infarction or any stroke; planned treatment with agents inhibiting blood clotting; planned use of ASA/Aspirin at doses above 150 mg daily; planned coronary, cerebrovascular, or peripheral arterial revascularization; patients with known bleeding disorders and patients who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin; history of intracranial bleeding at any time, or a history of bleeding from the gastrointestinal tract within the last 6 months or a major surgery within the last 30 days; patients with known severe liver disease or with kidney failure requiring dialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety efficacy - | — |
Secondary
| Measure | Time frame |
|---|---|
| safety efficacy exploratory - | — |
Countries
Africa, Asia except Japan, Europe, Japan, North America, Oceania, South America
Outcome results
None listed